New data presented at estro 2022 reinforce benefits of accuray cyberknife® and tomotherapy® platforms across a range of indications and complexities

More than 70 abstracts build on the clinical evidence supporting the use of these technologies sunnyvale, calif. , may 10, 2022 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that clinical studies continue to validate the versatility of the company's cyberknife® and tomotherapy® platforms, including the next-generation radixact® system, to accurately and efficiently treat a wide variety of indications of all complexities.
ARAY Ratings Summary
ARAY Quant Ranking